The first batch of domestic new crown special drugs in Shenzhen put into clinical treatment in Shenzhen

The first batch of new crown viruses and antibody combined treatment drugs arrived at the interviewee of the Third People's Hospital of Shenzhen

Zheng Mingda, a reporter from the Yangcheng Evening News: On July 11, the new crown and antibody Ambarabi Mipidumi and Romi Siwei's anti -combined therapy drug transfer ceremony was held in Shenzhen Third People's Hospital. This is the first batch of drugs supplied to the market after the commercialization of the domestic new crown special medicine. A total of 100 people were stored in a total of 100 people. The whole process was stored and transported in a cold chain environment of 2-8 ° C. It was successfully delivered to the hospital on July 9.

Full cold chain storage and transportation

Anbawei's Mipidumi and Romi Siwei Mipidumi is a non-competitive new severe acute respiratory response from the new type of coronary virus pneumonia (COVID-19) patients in the new type of coronary virus pneumonia (COVID-19) patients with Tsinghua University and Tsinghua University. System syndrome virus 2 (SARS-COV-2) monoclonal neutralized antibody. It was approved by the State Drug Administration in December 2021. It was listed on commercialization in China on July 7th. New crown antibody drugs developed.

In March of this year, the combined therapy was approved by the National Health and Health Commission and included in the "New Coronatte Virus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)", which was used to treat light and ordinary types of progress (including hospitalization or death) high risk (including hospitalization or death) high risk. Adults and adolescents (12-17 years old, weight ≥40 kg) new coronary virus infection (COVID-19) patients. Among them, the adolescents (12-17 years old, weight ≥40 kg) are approved by the attachment.

The previous clinical trial data of the 3rd phase of the world showed that compared with the placebo, the combination therapy of Anbawei's anti -anti -anti -Romi Savido anti -risk of the new crown outpatient patients with high risk of clinical progress was reduced by 80%. Scholars are significant. The first batch of drugs in the country has a total of 100 people in the country. The combined therapy for each person is composed of Anbawei's anti-anti-resistance 1000 mg and 1000 mg of Romi Siwei's anti-resistance.

82 -year -old patients have effective after medication

Data of the activation and chimiric virus experiments in multiple independent laboratories show that the main new coronary virus variable strains that are widely concerned about the major new coronary virus variants of Anbavir Mipida and Romi Siwei's anti -combined therapy have neutralized, including B. 1.1.529-BA.1 (Omicron, Omitron), and BA.1.1 and BA.2 (Omikon subtype varieties).

Lu Hongzhou, Dean of the Third People's Hospital of Shenzhen, introduced that at present, confirmation of further experiments of the combined therapy for BA.4/5 and BA.2.12.1, including the live virus analysis, is in progress.

At present, this new medicine has been taken the lead in Shenzhen Third People's Hospital. According to Liu Lei, secretary of the Party Committee of the Third People's Hospital of Shenzhen, a 82 -year -old diagnosis case in the hospital has successfully used the new crown and antibody Anbaweibu and Romi Siwei's combined therapy medicine, which became the commercialization of the drug. The first clinical user after listing.

It is reported that this case suffers from a variety of basic diseases such as hypertension, coronary heart disease, chronic heart failure, and the virus load is high and it is easy to develop to severe illnesses. At present, the various immune mechanisms of the elderly have been effectively improved, the amount of virus has decreased sharply, and the effect of medication is more obvious.

The first batch of Anbawei's Mipida and Romi Siwei Mipida will be transported to the forefront of the Third People's Hospital of Shenzhen to fight against the new crown pneumonia. It provides one more means, path and method for patients with severe patients. "Anbawei's Mipido and Romi Siweizabi only took 27 months from R & D to listing. It must be a miracle." Liu Lei said.

- END -